Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.39 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL488748 | 1.00 | IDO1 (0.59) | IDO1SLC6A2SLC6A4SLC6A3HDAC3 | |
| SCHEMBL75416 | 0.88 | IDO1 (0.46) | IDO1SLC6A2SLC6A4SLC6A3HDAC3 | |
| SCHEMBL28763543 | 0.84 | IDO1 (0.56) | IDO1SLC6A2SLC6A4SLC6A3HDAC3 | |
| SCHEMBL1538597 | 0.83 | IDO1 (0.63) | IDO1SLC6A2SLC6A4SLC6A3HDAC3 | |
| SCHEMBL3278241 | 0.81 | IDO1 (0.61) | IDO1SLC6A2SLC6A4SLC6A3HDAC3 | |
| SCHEMBL14774588 | 0.81 | IDO1 (0.56) | IDO1SLC6A2SLC6A4SLC6A3HDAC3 | |
| SCHEMBL17864241 | 0.79 | IDO1 (0.59) | IDO1SLC6A2SLC6A4SLC6A3HDAC3 | |
| SCHEMBL109671 | 0.79 | IDO1 (0.65) | IDO1SLC6A2SLC6A4SLC6A3HDAC3 | |
| SCHEMBL195156 | 0.79 | KDM1A (0.43) | IDO1SLC6A4GPR183 | |
| SCHEMBL8417818 | 0.79 | IDO1 (0.59) | IDO1SLC6A2SLC6A4SLC6A3HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025224512-A1 | NOVEL COMPOUND AS 17-BETA-HYDROXYSTEROID DEHYDROGENASE 13 (HSD17B13) INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 삼진제약주식회사 | 2025-10-30 | — | — | WO | disclosed |
| EP-4612131-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4561575-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-115594669-B | Parallel ring derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-11-05 | — | — | CN | disclosed |
| WO-2024175927-A1 | MC2R MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2024-08-29 | — | — | WO | disclosed |
| CN-115215823-B | FXR modulator, preparation method, pharmaceutical composition and application thereof | 北京百思致道管理顾问中心(有限合伙) | 2024-07-26 | — | — | CN | disclosed |
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024095003-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |
| CN-115594669-A | Fused ring derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-109963836-B | Deuterium atom substituted indole carboxamide derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-115215823-A | FXR (FXR) regulator and preparation method, pharmaceutical composition and application thereof | 青岛睿吉医疗技术有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-109485595-B | Hydrophilic group substituted indole formamide derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-114401968-A | Novel heterocyclic monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2022-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP4B1 | IDO1 1568/4885SLC6A2 4429/4885SLC6A4 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.